

Seattle Genetics, Inc. would like to inform you that the Centers for Medicare and Medicaid Services (CMS) has added ADCETRIS® (brentuximab vedotin) to their list of not otherwise classified (NOC) drugs file effective July 1, 2012. Below is the information found via the CMS website link:

Payment Allowance Limits for Medicare Part B Not Otherwise Classified (NOC) Drugs

Effective July 1, 2012 through September 30, 2012

Note 1: Payment allowance limits subject to the ASP methodology are based on 1Q12 ASP data.

Note 2: Providers should contact their local Medicare contractor processing the claim for the most appropriate unlisted/unclassified HCPCS code to use in reporting these drugs to Medicare.

Note 3: The absence or presence of a HCPCS code and the payment allowance limits in this table does not indicate Medicare coverage of the drug. Similarly, the inclusion of a payment allowance limit within a specific column does not indicate Medicare coverage of the drug in that specific category. These determinations shall be made by the local Medicare contractor processing the claim.

Drug Generic Name (Trade Name)	Dosage	Payment Limit	Notes
Brentuximab Vedotin	1 MG	\$95,400	Added July 2012

For further information regarding the CMS NOC price file please see the CMS website.

<http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2012ASPFiles.html>

For assistance with ADCETRIS® reimbursement or billing, please contact SeaGen Secure at (855) 473-2436 (Option 1).